Topics
previous
AI
Amazon
Image Credits:Signos(opens in a new window)
Apps
Biotech & Health
Climate
Image Credits:Signos(opens in a new window)
Cloud Computing
mercantilism
Crypto
Enterprise
EVs
Fintech
Fundraising
gismo
Gaming
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
societal
quad
startup
TikTok
Transportation
speculation
More from TechCrunch
Events
Startup Battlefield
StrictlyVC
newssheet
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
touch Us
Signos , a metabolic wellness weapons platform that apply a unique AI - railway locomotive with a continuous glucose monitor ( CGM ) to offer real - fourth dimension data and recommendations for healthy weight direction , has announce a successful $ 20 million Series B financing beat . The round was conduct by Cheyenne Ventures and GV ( Google Ventures ) , with additional investments from Dexcom Ventures and Samsung . It will enable Signos to expand its squad , extend its platform and behave further research on metabolic health .
Signos ’ mission is to address the corpulency and metabolic health crisis that currently afflicts those in the United States . More than 96 million Americans have prediabetes and an estimated 1 billion mass are externalise to have diabetes by 2050 . The company read the need for other detection and lifestyle changes is more decisive than ever .
The Signos app allows user to log their food intake and exercise levels , turn on the AI platform to learn how an individual ’s metabolism respond to various foods and physical fitness patterns . This information then provides personalized , data - driven recommendations based on an individual ’s unique metabolic visibility .
In an interview with TechCrunch , Sharam Fouladgar - Mercer , chief operating officer of Signos , shared his motivating behind the fellowship . Having struggle with his weight since childhood , Fouladgar - Mercer understand the challenges of weight departure and the inefficacy of a one - size of it - fits - all diet . His experiences inspired him to leverage CGM engineering to continue the benefits of glucose sixth sense to a broader population , include those living with type 2 diabetes .
“ This raw round of funding will allow us to expand our core team and platform and impart additional enquiry on metabolic wellness . The funding will allow us to progress to more prospective extremity , ” said Fouladgar - Mercer .
However , challenge stay on , the fellowship says . employ desirable prospect and making the Signos program widely available , particularly with the comparatively eminent cost of CGM engineering , are central area of focus for the company . Despite these challenges , Fouladgar - Mercer remains optimistic , stating , “ We ’re activated to continue to build something that can exchange lives for the good . ”
There ’s been quite a bit of interesting movement in this blank recently . At TechCrunch Disrupt this year , we sawHME Square take photograph - acoustics to the table as a way of measuring blood glucosewithout postulate to permeate the peel with a strand — much likeScanbo , which I covered almost two years ago . There are a figure of other startup in this space as well , includingLimbo . Ultimately , I believe this competition and subspecies to instauration is going to attend to the customers want to keep a cheeseparing oculus on their metabolic wellness .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
I was singular whether the chief operating officer ’s work on Signos had made him adapt his personal habits .
“ Yes and no . I fuck to bake sourdough staff of life in my destitute time ( yes , you may deplete bread when you ’re planning for a glucose - friendly diet ) , ” Fouladgar - Mercer state . “ But , when I do broil , I try out to plan when I eat up cabbage so I can do a short walk after to mitigate the glucose spike as needed . I think the key is not avoiding all carbs ; it ’s estimate out a sustainable diet and exercise plan that works for your unique metabolism . ”
With this Modern injectant of stock , Signos claims it is well - positioned to continue its pioneering piece of work in metabolic wellness and weight management , ply a much - need solution to a turn health crisis .
